Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytoplasmic membrane vesicles from <i>Clostridioides difficile</i> R20291 are remodeled by osmotic stress.

Frontiers in microbiology·2026
Same author

Coupling Far-Western Blotting with Peptide Microarrays Reveals Novel E-Cadherin Spore-Surface Ligands in <i>Clostridioides difficile</i>.

Journal of proteome research·2026
Same author

A Moving Target: Endoscopic Ultrasound Diagnosis of Live Fasciola hepatica Mimicking Distal Cholangiocarcinoma.

The American journal of gastroenterology·2026
Same author

Carbon monoxide-producing probiotic <i>Escherichia coli</i> attenuates HSV-1 skin disease.

iScience·2026
Same author

Development and Evaluation of Exosporium-Anchored Bioluminescent and Fluorescent Reporters for Tracking <i>Clostridioides difficile</i> Spores Formed <i>In Vivo</i>.

ACS synthetic biology·2026
Same author

Phylogenomic analysis of the collagen-like BclA proteins in <i>Clostridioides difficile</i>.

Applied and environmental microbiology·2026

Related Experiment Video

Updated: May 17, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

[Clostridium difficile associated infections: an updated view].

Cristian Hernández-Rocha1, Sebastián Naour, Manuel Alvarez-Lobos

  • 1Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile.

Revista Chilena De Infectologia : Organo Oficial De La Sociedad Chilena De Infectologia
|October 26, 2012
PubMed
Summary
This summary is machine-generated.

Clostridium difficile infections (CDI) cause significant antibiotic-associated diarrhea, with spores driving transmission. This review details CDI pathogenesis, epidemiology, and emerging strategies for detection, treatment, and prevention.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: May 17, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridium difficile is a major cause of antibiotic-associated diarrhea, leading to severe outcomes like pseudomembranous colitis and toxic megacolon.
  • Clostridium difficile-associated infections (CDAI) affect approximately 1% of hospitalized patients, with a notable mortality and relapse rate.
  • Pathogenesis involves enterotoxins TcdA and TcdB, and C. difficile spores are crucial for transmission and persistence.

Purpose of the Study:

  • To provide an updated review on Clostridium difficile infections (CDAI).
  • To cover mechanisms of pathogenesis, epidemiology, and risk factors.
  • To discuss advancements in detection, treatment, and prevention strategies.

Main Methods:

  • Literature review of recent advances in Clostridium difficile research.
  • Synthesis of information on pathogenesis, epidemiology, and clinical aspects.
  • Analysis of novel detection, therapeutic, and preventive approaches.

Main Results:

  • Clostridium difficile infections (CDAI) are linked to virulence factors TcdA and TcdB and spore transmission.
  • Significant morbidity and mortality associated with CDAI in hospitalized patients.
  • Recent progress in diagnostics, therapies, and prevention offers hope for reducing CDAI frequency.

Conclusions:

  • Understanding Clostridium difficile pathogenesis and spore dynamics is key to control.
  • Novel detection methods and therapies are emerging to combat CDAI.
  • Integrated strategies for prevention are essential to reduce the incidence and impact of Clostridium difficile infections (CDAI).